Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Trends in Peritoneal Dialysis Use in the United States after Medicare Payment Reform.

Sloan CE, Coffman CJ, Sanders LL, Maciejewski ML, Lee SD, Hirth RA, Wang V.

Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1763-1772. doi: 10.2215/CJN.05910519. Epub 2019 Nov 21.

PMID:
31753816
2.

The 7 Habits of Highly Effective Cost-of-Care Conversations.

Sloan CE, Ubel PA.

Ann Intern Med. 2019 May 7;170(9_Supplement):S33-S35. doi: 10.7326/M19-0537. No abstract available.

PMID:
31060062
3.

Jonathan Gerwyn Evans.

Khan KN, Ogden CF, Sloan CEL, Goodson C.

BMJ. 2017 Jul 4;358:j3224. doi: 10.1136/bmj.j3224. No abstract available.

PMID:
28676503
4.

Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ, Tebas P.

HIV Med. 2017 Jul;18(6):412-418. doi: 10.1111/hiv.12518. Epub 2017 Apr 26.

5.

Referring Provider Perceptions of Standardized Reporting for Possible Abdominal Cancer.

Sloan CE, Chadalavada SC, Lalevic D, Cook TS, Zafar HM.

J Am Coll Radiol. 2017 May;14(5):654-658.e3. doi: 10.1016/j.jacr.2016.10.022. Epub 2017 Jan 28. No abstract available.

PMID:
28143749
6.

Initial Effectiveness of a Monitoring System to Correctly Identify Inappropriate Lack of Follow-Up for Abdominal Imaging Findings of Possible Cancer.

Santo EC, Dunbar PJ, Sloan CE, Cook TS, Lalevic D, Zafar HM.

J Am Coll Radiol. 2016 Dec;13(12 Pt A):1505-1508.e2. doi: 10.1016/j.jacr.2016.06.016. Epub 2016 Aug 28. No abstract available.

PMID:
27577595
7.

A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.

Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M.

PLoS One. 2016 Apr 6;11(4):e0153016. doi: 10.1371/journal.pone.0153016. eCollection 2016.

8.

Code Abdomen: An Assessment Coding Scheme for Abdominal Imaging Findings Possibly Representing Cancer.

Zafar HM, Chadalavada SC, Kahn CE Jr, Cook TS, Sloan CE, Lalevic D, Langlotz CP, Schnall MD.

J Am Coll Radiol. 2015 Sep;12(9):947-50. doi: 10.1016/j.jacr.2015.04.005. Epub 2015 Jun 27. No abstract available.

9.

Appropriateness of expectorated sputum cultures in the hospital setting.

Sloan CE, Bernard S, Nachamkin I.

Diagn Microbiol Infect Dis. 2015 Sep;83(1):74-6. doi: 10.1016/j.diagmicrobio.2015.05.009. Epub 2015 May 21.

PMID:
26032431
10.

Assessment of follow-up completeness and notification preferences for imaging findings of possible cancer: what happens after radiologists submit their reports?

Sloan CE, Chadalavada SC, Cook TS, Langlotz CP, Schnall MD, Zafar HM.

Acad Radiol. 2014 Dec;21(12):1579-86. doi: 10.1016/j.acra.2014.07.006. Epub 2014 Aug 30.

11.

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y; Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators.

AIDS. 2012 Jan 2;26(1):45-56. doi: 10.1097/QAD.0b013e32834dce6e.

12.

Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV.

Chu J, Sloan CE, Freedberg KA, Yazdanpanah Y, Losina E.

AIDS Res Ther. 2011 Mar 10;8:14. doi: 10.1186/1742-6405-8-14.

13.

Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.

Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA; Cepac US And Actg A5164 Investigators.

HIV Clin Trials. 2010 Sep-Oct;11(5):248-59. doi: 10.1310/hct1105-248.

14.

Routine HIV screening in France: clinical impact and cost-effectiveness.

Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD.

PLoS One. 2010 Oct 1;5(10):e13132. doi: 10.1371/journal.pone.0013132.

15.

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA; CEPAC-International Investigators.

Antivir Ther. 2010;15(3):351-61. doi: 10.3851/IMP1542.

16.

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP.

Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095.

Supplemental Content

Loading ...
Support Center